Alnylam Pharmaceuticals Inc (ALNY) Page

Alnylam Pharmaceuticals Inc (ALNY)

Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO™ (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.

ALNY SEC Filing Email Alerts Service

ALNY — Key Stats (updated Fri., Aug. 12, 10:18 AM)

Company Name:
Alnylam Pharmaceuticals Inc
Website:
www.alnylam.com
Sector:
Drugs & Pharmaceuticals
Number of ETFs Holding ALNY:
57
Total Market Value Held by ETFs:
$3.09B
Total Market Capitalization:
$27.85B
% of Market Cap. Held by ETFs:
11.08%

ALNY — News

ALNY — Price Chart

ALNY — Current Quote

Quotes delayed 20 minutes

Free ALNY Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Avg. Broker Rec.

Buy (3.26 out of 4)
35th percentile

(ranked lower than approx. 65% of all stocks covered)

Analysts' Target Price:
ALNY Stock Forecast

Based on Zacks ABR data;
powered by Xignite

ALNY — Performance

Alnylam Pharmaceuticals Inc (ALNY) Page | The Online Investor Page | www.TheOnlineInvestor.com

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.